The company said, “The Company remains committed to pursuing immediate growth opportunities that are both profitable and supported by its streamlined, more adaptable operating base. This includes ongoing expansion into international markets with its latest product offerings: An enhanced HbA1c testing solution for diabetes care; Extending the availability of its TrinScreen HIV tests to new countries. The Company is also advancing the commercialisation of its key strategic growth projects currently in development, including: Its next-generation continuous glucose monitor, CGM+; EpiCapture, the company’s PCR-based epigenetic liquid biopsy test for monitoring the risk of prostate cancer progressing to more aggressive forms of the disease; and PrePsia, an innovative early pregnancy screening test designed to assess the risk of preeclampsia-a potentially life-threatening condition for both mother and baby.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech awarded order for 9M TrinScreen HIV tests
- Trinity Biotech Accelerates Global Rollout of High-Capacity HbA1c Column System After New Regulatory Clearances
- Trinity Biotech expands global rollout of high-capacity column system
- Trinity Biotech Secures WHO Approval for Offshore Manufacturing of HIV Test
- Trinity Biotech Collaborates to Enhance Prostate Cancer Test